The reduction of hypoglycemia risk (66.9%) and dissatisfaction with prior therapies (55.8%) were also prominent factors, indicating that despite relatively preserved endogenous insulin production in T2DM, safety and convenience remain key drivers in treatment decisions. This evidence concerns the gene INS and type 2 diabetes mellitus.